ClinicalTrials.gg
RecruitingNCT05331170VMRUpdated Jan 28, 2025

Viral Mucosal Reprogramming

A Phase 2 interventional study of Research Grade RG-RV in Asthma, Allergic Rhinitis and Cat Allergy, sponsored by The University of Texas Medical Branch, Galveston. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by The University of Texas Medical Branch, Galveston · Phase 2, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.

02

Conditions studied

  • Asthma
  • Allergic Rhinitis
  • Cat Allergy
  • Healthy

Keywords

  • Asthma
  • Allergy
  • Allergic
  • Rhinitis
  • Airway
  • Cat dander
  • Respiratory
03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's planned enrollment of 75 is close to the median of 78 across 3,341 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 38 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Healthy Normal Control Group

  1. Subject must be able to understand and provide
  2. Age: 18-60 inclusive
  3. Sex: M or F
  4. No history of asthma, , rhinitis, or other respiratory disease
  5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote.
  6. No history of diabetes or cardiovascular disease
  7. Negative ImmunoCAP test to regionally relevant allergen panel obtained at Screening. Alternatively, documented history of a negative skin test or negative specific IgE obtained within the past 12 months.

Allergic Rhinitis Group

  1. Subject must be able to understand and provide informed consent
  2. Age: 18-60 inclusive
  3. Sex: M or F
  4. No history of asthma, COPD, or other clinically important respiratory disease
  5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote
  6. No history of diabetes or cardiovascular disease
  7. History of rhinitis, physician diagnosed, plus one of the following criteria within the past 12 months
  8. Seasonal or perennial nasal congestion or sneezing
  9. Seasonal or perennial conjunctival infection or watering
  10. No evidence of airway obstruction (:FVC ≥ lower limit of normal)
  11. Positive ImmunoCAP test to cat. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criterion. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.

Allergic Asthma Group

Inclusion Criteria

  1. Subject must be able to understand and provide informed consent
  2. Age: 18-60 inclusive
  3. Sex: M or F
  4. No history of COPD or other clinically important respiratory disease other than asthma
  5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote
  6. No history of diabetes or cardiovascular disease
  7. History of mild-moderate asthma, physician diagnosed, plus one of the following criteria within the past 12 months

    1. Airway obstruction (FEV1: FVC \<0.6) that is significantly (at least 12% change from baseline, ATS criteria) reversible after 4 puffs of albuterol (obtained at Screening Visit or documented historical testing performed with the past 12 months)
    2. Requiring ICS for control of asthma for at least 30 days within the past 12 months
  8. Positive ImmunoCAP test to cat dander. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criteria. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.
  9. Results of the CBC do not show clinically important abnormalities

Exclusion Criteria:

Healthy Group Normal Group

  1. Inability or unwillingness of a participant to comply with study protocol
  2. Currently taking inhaled , leukotriene modifier, or antihistamines for respiratory disease.
  3. Neutralizing Ab to RV16 greater than or equal to 1:8
  4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at the screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
  5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are e.g. post-chemotherapy, ).
  6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).

Allergic Rhinitis Group

  1. Inability or unwillingness of a participant to comply with study protocol
  2. Currently using inhaled steroids, or oral montelukast for respiratory disease
  3. Neutralizing Ab to RV16 greater than or equal to 1:8
  4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
  5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
  6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
  7. Subjects who have received immunosuppressive treatment within the last 12 months
  8. is greater than 35
  9. History of symptoms consistent with a viral URI within the past 21 days
  10. Results of the CBC do not show clinically important abnormalities
  11. Family history or medical history of liver disease or bleeding disorders
  12. Have not received systemic corticosteroids for 3months prior to Screening
  13. Antiplatelet agents other than aspirin
  14. Subjects who have a positive COVID-19 test will be excluded for 8 weeks

Allergic Asthma Group

  1. Inability or unwillingness of a participant to comply with study protocol
  2. Currently taking medications for respiratory diseases other than ICS, montelukast, or rescue albuterol or LABAs.
  3. Neutralizing Ab to RV16 greater than or equal to 1:8
  4. FEV1: FVC ratio less than 0.6, or FEV1 less than 60% predicted
  5. Recent (\<30 days) exacerbation of asthma requiring systemic corticosteroids
  6. ICS greater than fluticasone 500 mcg/day or its equivalent (GINA 2019 table) at screening.
  7. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
  8. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
  9. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
  10. Subjects who have received immunosuppressive treatment within the last 12 months
  11. BMI is greater than 35
  12. History of symptoms consistent with a viral URI within the past 21 days
  13. Family history or medical history of liver disease or bleeding disorders
  14. Have not received systemic corticosteroids for 3 months prior to Screening
  15. Have an ACT score >19 at the time of enrollment.
  16. Antiplatelet agents other than aspirin
  17. Subjects who have a positive COVID-19 test will be excluded for 8 weeks
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Healthy

    Subjects without asthma, COPD, rhinitis and with negative allergen test

    Biological: Research Grade RG-RV

  • Active comparator
    Allergic Rhinitis

    Subjects without asthma, COPD and with positive allergen test

    Biological: Research Grade RG-RV

  • Active comparator
    Allergic Ashthma

    Subjects with asthma and positive allergen test

    Biological: Research Grade RG-RV

Interventions

  • BiologicalResearch Grade RG-RV

    Exploration of the effects of RV inoculation on human airway mucosal programming in vivo

06

What researchers measure

Primary outcomes

  1. ZEB-1 Expression

    Q-PCR

    Time frame: Immediate

  2. Type III Interferon

    Q-RT-PCR

    Time frame: Immediate

  3. PD-L1 Expression

    Q-RT-PCR

    Time frame: Immediate

  4. RV16 Viral Titer

    Plaque Assays

    Time frame: 48 hours after inoculation

Secondary outcomes

  1. CD8 T cells in bronchoalveolar lavage fluid

    Proportion and number of CD8+ T cells

    Time frame: Immediate and 48hrs post RV16 inoculation

  2. Airway Remodeling

    Lamina reticularis thickness

    Time frame: Immediate and 48 hrs post RV16 inoculation

  3. URI Cold Symptoms

    WURSS21 Questionnaire

    Time frame: Immediate and up to 7 days following inoculation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for May 2027, 48 months after the start.

Of 61 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 48 months is close to that.

Counting every sponsor, half of 198 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2022
First posted
Apr 15, 2022
StartActual
Apr 27, 2023
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05331170
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Apr 27, 2023
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jan 28, 2025

Study contacts

Lisa Sweeney, RN
Contact
lanemeth@utmb.edu
409-747-5871
William J. Calhoun, MD
principal investigator · University of Texas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion